Advertisement

Topics

Latest "Rosuvastatin Placebo Critically" News Stories

08:34 EDT 20th October 2018 | BioPortfolio

Here are the most relevant search results for "Rosuvastatin Placebo Critically" found in our extensive news archives from over 250 global news sources.

More Information about Rosuvastatin Placebo Critically on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Rosuvastatin Placebo Critically for you to read. Along with our medical data and news we also list Rosuvastatin Placebo Critically Clinical Trials, which are updated daily. BioPortfolio also has a large database of Rosuvastatin Placebo Critically Companies for you to search.

Showing "Rosuvastatin Placebo Critically" News Articles 1–25 of 1,100+

Friday 19th October 2018

DOULEUR CHRONIQUE : Des pilules placebo pour 30% des patients ?

Des pilules au sucre ou un simple placebo pour soulager la douleur chez certains patients souffrant de douleur chronique ? Il semblerait que ce soit efficace pour une partie des patients, concluent ces chercheurs de Chicago : « Les pilules placebo soulagent la douleur aussi efficacement que les médicaments pour la moitié des patients souffrant de douleur chronique […]


Thursday 18th October 2018

Kala Pharmaceuticals to Present at the 2018 American Academy of Ophthalmology (AAO) Annual Meeting and at the Ophthalmology Innovation Summit at AAO

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that it will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO) meeting taking place on October 25, 2018. Data from a Phase 3 clinical trial conducted with KPI-121 0.25% for the short-term treatment of dry eye disease and data from the Phase 3 cl...

Oral DS107 Found to Reverse the Molecular Signature of Moderate to Severe Atopic Dermatitis Patients in a Phase 2 Trial

DS Biopharma (DS), a privately held biopharmaceutical company, today announced that oral treatment with DS107 reversed the molecular signature of Atopic Dermatitis (AD) patients in a phase 2b clinical trial comprising 319 patients with moderate to severe AD (ADvance Study). DUBLIN (PRWEB) October 18, 2018 DS Biopharma (DS), a privately held biopharmaceutical company, today announced that oral tre...


AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure

AELIX Therapeutics will investigate the safety, immunogenicity, and efficacy of AELIX Therapeutics’ HTI vaccine and Gilead´s Toll-Like Receptor 7 agonist vesatolimod (GS-9620) in HIV-infected individuals AELIX Therapeutics S.L. (“AELIX”), a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for H...

Wednesday 17th October 2018

Ironshore to Present New Data at The 65TH Annual AACAP Meeting

Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and the global leader in the development of novel treatments for

XIFIN Introduces RPM 10, Industry’s First Machine Learning-Enabled Revenue Cycle Management Solution for Diagnostic Providers

New capabilities—including advanced analytics and data visualization—optimize operations, increase revenue, and fulfill compliance and reporting requirements XIFIN, Inc. today unveiled XIFIN Revenue Performance Management (RPM) 10 to help diagnostic providers improve revenue, performance, and client and

Oragenics, Inc. Receives Clearance to Enroll Patients in Belgium into Its Phase 2 Clinical Trial of AG013 for Oral Mucositis

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced it has received clearance to enroll patients residing in Belgium from the Belgian Health Authority, The Federal Agency for Medicines and Health Products (FAMHP), into its P...

Bristol-Myers Squibb to Showcase Immunoscience Research and Biomarker-Guided Treatment Approaches at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting

- Growing body of evidence, including real-world studies, points to the clinical significance of anti-citrullinated protein antibody (ACPA) as a biomarker of poor prognosis in patients with rheumatoid arthritis (RA) - AVERT-II data provides new insights into treatment with ORENCIA® (abatacept) in patients with newly diagnosed ACPA-positive RA ...

DIA Drives Debates and Solutions at the Crossroads of Healthcare

DIA Europe 2019 annual meeting heads to Vienna, Austria in February DIA, founded as the Drug Information Association, announced three keynote speakers for the upcoming

Tuesday 16th October 2018

vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Results of the Azeliragon Phase 3 STEADFAST Trial to be Presented during Oral Session Subgroup Data Discussing the Effect of Azeliragon in Patients with Dementia and Diabetes to be Presented during Poster Session vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage

KOL Perspectives: Update on Novel Candidates in Development for Lupus [Report Updated: 30052018] Prices from USD $2500

KOL Perspectives: Update on Novel Candidates in Development for LupusSummaryThis KOL Insight briefing provides an update on novel candidates in development for Lupus.The briefing includes analysis of KOL opinion on the following topic areas Atacicept's efficacy data in SLE Atacicept's flare data in SLE Patients most suitable for atacicept treatment Targeting the IgE pathway in lupus Omalizumab's...

Clinical Trials Support Efficacy of Tretinoin Lotion for Tx of Acne

TUESDAY, Oct. 15, 2018 -- Tretinoin 0.05 percent lotion (ALTRENO Lotion) provides statistically significant improvement in patients with moderate-to-severe acne, compared to placebo, according to two phase 3 studies published in the October issue of...

Velicept Therapeutics Raises an Additional $15 Million in Series B Round, Initiates Phase 2b Study Evaluating Once Daily Dosing of Solabegron in Patients with Overactive Bladder (OAB) and Receives Issuance of Additional U.S. Patent

-Additional Funding to Advance Phase 2b Development Program in OAB- -Enrollment for Second Phase 2 Study Well Underway- -Issuance of U.S. Patent No. 10,065,922 Further Expands Velicept’s Portfolio Covering Solabegron- Velicept Therapeutics, a privately-held clinical stage pharmaceutical company dedicated to the development of best-i...

U.S. FDA Grants LYNPARZA® (olaparib) Orphan Drug Designation for Pancreatic Cancer

Fourth Orphan Drug Designation in the U.S. for AstraZeneca and Merck’s LYNPARZA AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) for LYNPARZA for the treatment of pancreatic cancer. LYNPARZA is currently being inv...

A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus

Monday 15th October 2018

[Articles] Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial

TMV remained stable in patients with spinal and bulbar muscular atrophy after being given BVS857 for 12 weeks. The intervention was associated with high incidence of immunogenicity and did not improve muscle strength or function. Additional studies might be needed to assess the efficacy of activating the IGF-1 pathway in this disease.

Advicenne Receives Health Canada Clearance to Extend its Pivotal Phase III Trial of ADV7103 in Canada

Regulatory News: Advicenne (Paris:ADVIC), a specialty pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announced today that it has received a No Objection Letter to extend its ARENA-2 pivotal Phase III trial for the treatment of distal Renal Tubular Ac...

PellePharm Presents Updated Data from Two Phase 2 Studies Demonstrating the Potential of Patidegib Topical Gel to Treat Basal Cell Carcinomas in Patients with Gorlin Syndrome and in Patients with Non-Gorlin Sporadic BCCs

--Study Results Presented at NORD’s Rare Diseases and Orphan Products Breakthrough Summit 2018 -- PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare skin conditions at their source, today presented updated clinical data from two Phase 2 studies of patidegib topical gel in a poster ses

FluGen Completes Dosing of Phase 2 Study to Assess Effectiveness of Novel Influenza Vaccine Designed to Protect Against Mismatched Strains

—Influenza challenge virus genetically drifted by six years from vaccine strain— FluGen, Inc. announced today that all subjects have completed dosing in a first-of-its-kind clinical study which challenged subjects with an influenza virus that was intentionally mismatched by six years from the influenza strain utilized in FluGen’s M2SR vaccine. ...

Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients

— Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101 — Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study, with Regeneron

Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of its lead antifungal rezafungin will be presented at the 2018 Hot Topics in Infectious Diseases (HTIDE) Conference to be held in Mestre, Venice from October 25-26, 2018. Rezafungin is the ...

Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran

− Topline Results on Primary Endpoint of Annualized Attack Rate Expected in Early 2019 – − Company Plans to Initiate a Rolling Submission of an NDA in 2018 with Addition of Full Clinical Results in Mid-2019 in Support of a Full Approval – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics com...

Health innovation system is broken and failing patients, new report argues

The pharmaceutical industry is incentivised to set high prices and deliver short-term returns to shareholders, rather than focusing on riskier, longer-term research which leads to critically needed therapeutic advances; according to a new report published by the UCL Institute for Innovation and Public Purpose, in collaboration with in collaboration with STOPAIDS, Global Justice Now and Just Treatm...

Karuna Announces First Patient Dosed in Phase 2 Study of Lead Product Candidate KarXT for the Treatment of Schizophrenia

Phase 2 study aims to reproduce significant efficacy previously observed in schizophrenia trial with xanomeline alone Company also announces successful Phase 1 study of proprietary xanomeline and trospium chloride co-formulation, which will be used in Phase 2 study Karuna Pharmaceuticals, Inc. (“Karuna”), focused on target...

Sunday 14th October 2018

Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 2018

- Satralizumab added to baseline therapy significantly reduced risk of relapse - Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that results from the phase III study of satralizumab (development code: SA237), SAkuraSky Study (NCT02028884), were presented at the Congress of European Committee for Treatment and Research in


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks